10P - Efficacy of tumor treating field therapy alone and in combination with doxorubicin in cellular model of breast cancer
|Date||17 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Basic Science
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573|
N. Gharaee, M. Habibpour, H. Sepehri, L. Delphi
Tumor treating fields (TTFs) are alternating fields with low intensity and intermediate frequency, that are used as a novel treatment for cancer therapy. TTFields lead to disruption in mitotic process and inhibit the proliferation of cancer cells. In the present study the effect of TTF therapy in cellular model of breast cancer is investigated. For this goal TTFields alone and in combination with doxorubicin as a chemical drug were examined.
MDA-MB-231 human breast cancer cells was exposed to TTFields for a duration of 30hours.TTFields also applied when cells were treated with doxorubicin in IC10 dose. The cells proliferation ratio was assessed after 72h.
Treatment with tumor treating fields inhibits the proliferation of cancer cells significantly. The optimal frequency that caused the most inhibitory effect was determined to be 150kHz. Combination of TTF therapy with using of optimal frequency and treatment with doxorubicin in IC10 dose led to further decrease in proliferation, compared to TTF therapy alone. Moreover, the sensitivity to chemotherapeutic agent was increased by the aid of TTFields.
These findings demonstrated that TTFields contain efficiency to arrest cancer cells proliferation. These results also show that TTFields can support chemical drug efficiency. Our studies indicate that, using TTF co-administrated with doxorubicin can be used as an alternative strategy for cancer therapy in breast cancer cases to improve the effects of the drugs and increase the sensitivity of cancer cells.
Clinical trial indentification
Legal entity responsible for the study
Ministry of Science, Research and Technology Tehran University
Biology Department of Tehran University
All authors have declared no conflicts of interest.